| Literature DB >> 28068087 |
Niall Igoe1, Elliott D Bayle1, Oleg Fedorov2, Cynthia Tallant2, Pavel Savitsky2, Catherine Rogers2, Dafydd R Owen3, Gauri Deb4, Tim C P Somervaille4, David M Andrews5, Neil Jones6, Anne Cheasty6, Hamish Ryder6, Paul E Brennan2, Susanne Müller2,7, Stefan Knapp2,7,8, Paul V Fish1.
Abstract
The BRPF (bromodomain and PHD finger-containing) family are scaffolding proteins important for the recruitment of histone acetyltransferases of the MYST family to chromatin. Evaluation of the BRPF family as a potential drug target is at an early stage although there is an emerging understanding of a role in acute myeloid leukemia (AML). We report the optimization of fragment hit 5b to 13-d as a biased, potent inhibitor of the BRD of the BRPFs with excellent selectivity over nonclass IV BRD proteins. Evaluation of 13-d in a panel of cancer cell lines showed a selective inhibition of proliferation of a subset of AML lines. Pharmacokinetic studies established that 13-d had properties compatible with oral dosing in mouse models of disease (Fpo 49%). We propose that NI-42 (13-d) is a new chemical probe for the BRPFs suitable for cellular and in vivo studies to explore the fundamental biology of these proteins.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28068087 DOI: 10.1021/acs.jmedchem.6b01583
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446